Friday, Jan 26, 2024 · SEC filings
What the smart money revealed on Jan 26
487 insider filings came in. We hid 40 planned (10b5-1) sellers and 369 people whose filings were routine, like grants and tax withholding.
Adicet Bio (ACET) Director Carl Gordon bought $7.5M
3.12M shares on the open market. Not a grant or an option exercise. Their past buys: 2 of 3 checked quarters beat the typical stock 6 months later.
Texas Capital Bancshares (TCBI) Director Robert Stallings bought $171K
9,000 shares on the open market. Not a grant or an option exercise. Their past buys: 7 of 9 checked quarters beat the typical stock 6 months later.
Perspective Therapeutics (CATX) Chief Medical Officer Markus Puhlmann bought $140K
280,000 shares on the open market. Not a grant or an option exercise.
Texas Capital Bancshares (TCBI) Director Laura Whitley bought $125K
2,000 shares on the open market. Not a grant or an option exercise.
Procter & Gamble (PG) Chief Brand Officer Marc Pritchard sold $15.6M
Not marked as a planned 10b5-1 sale. Most of the shares sold came from stock options they exercised the same day. Still holds 163,428 shares directly.
Procter & Gamble (PG) CEO - Baby Ma. Francisco sold $11.4M
Not marked as a planned 10b5-1 sale. Most of the shares sold came from stock options they exercised the same day. Still holds 973 shares directly.
Sempra (SRE) Chairman Jeffrey Martin sold $2.42M
Not marked as a planned 10b5-1 sale. Sold 100% of the shares they held directly. Still holds 2 shares.
Show 15 more real buys
Show 31 more real sales
13F season
Holdings as of Dec 31, 2023 are due Feb 14
49 funds have filed so far. 40 filed for the quarter before.
Biggest real insider buys, Jan 20–26
Open-market buys by officers and directors, filed in the 7 days up to Jan 26.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.